Crohn’s disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab

The American Journal of Gastroenterology

from Gastroenterology via xlomafota13 on Inoreader http://ift.tt/2d8LPXJ
via IFTTT